Eli Lilly becomes the first health-care company to reach a $1 trillion market cap, briefly hitting the mark in morning trading before retreating. Stock has climbed over 36% this year due to success of weight loss injection Zepbound and diabetes treatment Mounjaro, driving eye-popping sales growth for the company.

Eli Lilly’s stock has soared on the back of the success of its drugs Mounjaro and Zepbound. Demand is expected to grow as approvals for the treatments’ uses and insurance coverage expand. Mounjaro drew in $6.52 billion in revenue in the third quarter, while Zepbound posted $3.59 billion in sales.

Eli Lilly expects an oral version of its popular drugs to hit the market next year, anticipating continued growth in the weight loss drug market, which analysts believe could be worth more than $150 billion by the early 2030s. Despite competition from Novo Nordisk and Pfizer, Eli Lilly remains a dominant player in the space.

Founded in 1876, Eli Lilly has been at the forefront of diabetes treatment, introducing the world’s first commercial insulin in 1923. The company became publicly traded on the NYSE in 1952 and has relied on successful products like insulins, Prozac, and the earliest polio vaccine for revenue. Eli Lilly saw success with tirzepatide as Mounjaro for diabetes and Zepbound for obesity, competing with Novo Nordisk’s offerings.

Read more at CNBC: Eli Lilly hits $1 trillion market value, first for health care company